Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP4 | P12644 | 7/20 | 0.63 |
| ▸ | ACVR1 | Q04771 | 14/20 | 0.56 |
| ▸ | KDR | P35968 | 7/20 | 0.56 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.56 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 0.56 |
| ▸ | ACVR1B | P36896 | 13/20 | 0.56 |
| ▸ | ACVRL1 | P37023 | 12/20 | 0.56 |
| ▸ | BMPR1B | O00238 | 10/20 | 0.56 |
| ▸ | BMPR1A | P36894 | 10/20 | 0.56 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.56 |
| ▸ | BMPR2 | Q13873 | 3/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.52 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21156307 | 0.85 | ACVR1 (0.62) | BMP4ACVR1KDRTGFBR1PRKAB1 | |
| SCHEMBL23962001 | 0.82 | BMP4 (0.69) | BMP4ACVR1KDRTGFBR1PRKAB1 | |
| SCHEMBL11953449 | 0.79 | BMP4 (1.00) | BMP4ACVR1KDRTGFBR1PRKAB1 | |
| SCHEMBL17538466 | 0.78 | BMP4 (0.70) | BMP4ACVR1KDRTGFBR1PRKAB1 | |
| SCHEMBL11953445 | 0.77 | BMP4 (1.00) | BMP4ACVR1KDRTGFBR1PRKAB1 | |
| SCHEMBL17531593 | 0.77 | BMP4 (0.82) | BMP4ACVR1KDRTGFBR1PRKAB1 | |
| SCHEMBL17538465 | 0.76 | BMP4 (0.69) | BMP4ACVR1KDRTGFBR1PRKAB1 | |
| SCHEMBL12779978 | 0.75 | BMP4 (0.82) | BMP4ACVR1KDRTGFBR1PRKAB1 | |
| SCHEMBL12779920 | 0.75 | BMP4 (0.82) | BMP4ACVR1KDRTGFBR1PRKAB1 | |
| SCHEMBL11953447 | 0.72 | BMP4 (1.00) | BMP4ACVR1KDRTGFBR1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | BMP1, BMPR2, BMP2 | BMP4 6/4885ACVR1 13/4885KDR 149/4885 |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | BMP1, BMPR2, BMP2 | BMP4 6/4885ACVR1 13/4885KDR 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.